Relationship of shear wave elastography anisotropy with tumor stem cells and epithelial-mesenchymal transition in breast cancer

Leng, Xiaoling; Japaer, Rexida; Zhang, Haijian; Yeerlan, Mila; Ma, Fucheng; Ding, Jianbing

doi:10.1186/s12880-021-00707-z

Table 5 Differences in SWE parameters of cross and longitudinal section in different clinicopathological characteristics

From: Relationship of shear wave elastography anisotropy with tumor stem cells and epithelial-mesenchymal transition in breast cancer

Items	Grouping	E-maximum cross section diameter	N	E-maximum longitudinal section diameter	Emax (cross section)	Emax (longitudinal section)	Emean (cross section)	Emean (longitudinal section)	Esd (cross section)	Esd (longitudinal section)
Age (year)	≤ 46	19.577 ± 5.946	59	18.900 ± 0.954	102.180 ± 57.435	101.156 ± 62.885	68.338 ± 38.690	71.626 ± 40.393	16.362 ± 9.196	19.462 ± 15.969
Age (year)	> 46	18.695 ± 6.269	60	17.965 ± 0.856	102.108 ± 62.454	96.738 ± 61.718	65.408 ± 42.831	68.068 ± 42.079	15.590 ± 9.098	18.168 ± 13.044
Menopausal state	Premenopause	19.664 ± 5.602	75	18.907 ± 5.804	103.324 ± 57.324	68.109 ± 38.616	68.584 ± 37.924	68.207 ± 36.522	16.125 ± 8.773	18.025 ± 13.873
Menopausal state	Post menopause	73.529 ± 50.564	44	17.325 ± 5.308	99.438 ± 65.864	62.892 ± 46.807	62.892 ± 46.807	73.529 ± 50.564	15.617 ± 9.985	20.596 ± 15.957
Clinical stage	≤ Stage 2	18.859 ± 5.564	64	18.391 ± 5.528	88.450 ± 52.468	95.564 ± 59.539	58.418 ± 35.578	67.420 ± 38.675	13.959 ± 7.991	18.530 ± 14.954
Clinical stage	> Stage 3	19.471 ± 6.759	55	18.471 ± 5.927	119.357 ± 64.277*	103.137 ± 65.455	77.460 ± 44.425*	72.846 ± 44.196	18.500 ± 9.860*	19.154 ± 14.075
Histological grade	Level 1	17.963 ± 4.995	27	16.700 ± 4.955	50.400 ± 17.907	56.763 ± 28.027	30.338 ± 13.930	40.775 ± 25.886	10.494 ± 1.756	12.281 ± 3.770
	Level 2	18.000 ± 5.664	45	17.689 ± 5.234	96.383 ± 51.845	108.626 ± 70.617	61.483 ± 31.936	74.477 ± 43.752	14.114 ± 7.571	21.143 ± 19.473
	Level 3	21.230 ± 6.902	47	20.407 ± 6.314	139.881 ± 61.615**	112.259 ± 55.712**	95.441 ± 42.337**	81.470 ± 38.276**	21.748 ± 10.643**	19.870 ± 9.432*
Intraductal carcinoma	No	19.390 ± 6.121	70	18.798 ± 5.693	101.435 ± 57.772	96.868 ± 61.691	66.998 ± 39.623	68.685 ± 39.943	15.585 ± 8.789	18.838 ± 15.903
Intraductal carcinoma	Have	18.864 ± 6.123	49	18.046 ± 5.698	102.869 ± 62.252	101.023 ± 62.922	66.708 ± 42.105	70.992 ± 42.605	16.367 ± 9.499	18.774 ± 13.074
Lymph nodes	Non-metastasis	17.159 ± 5.495	47	16.906 ± 5.452	96.618 ± 57.523	116.771 ± 81.259	62.459 ± 35.074	80.788 ± 50.560	14.435 ± 8.952	23.641 ± 22.570
Lymph nodes	Metastasis	19.671 ± 6.173	72	18.844 ± 5.702	103.658 ± 60.580	94.024 ± 55.318	68.060 ± 42.174	66.818 ± 37.939	16.392 ± 9.161	17.481 ± 11.237
Hormone receptor status	ER positive group	18.725 ± 5.861	78	18.279 ± 5.425	101.821 ± 58.772	99.554 ± 61.429	65.410 ± 39.100	69.748 ± 39.773	15.694 ± 8.288	18.885 ± 14.704
Hormone receptor status	ER negative group	20.059 ± 6.344	41	18.900 ± 5.860	106.862 ± 61.826	100.000 ± 65.094	71.738 ± 43.631	70.910 ± 44.605	17.107 ± 10.334	19.245 ± 14.668

Items	Grouping	E-maximum cross section diameter	N	E-maximum longitudinal section diameter	Eratio (cross section)	Eratio (longitudinal section)	Paracancer E-maximum cross section diameter	Paracancer E-maximum longitudinal section diameter	Paracancer Emax (cross section)	Paracancer Emax (longitudinal section)
Age (year)	≤ 46	19.577 ± 5.946	59	18.900 ± 0.954	9.015 ± 6.049	8.803 ± 5.932	15.803 ± 6.706	14.226 ± 4.892	8.903 ± 3.840	8.790 ± 3.348
Age (year)	> 46	18.695 ± 6.269	60	17.965 ± 0.856	8.535 ± 6.194	7.405 ± 4.391	15.980 ± 7.937	16.318 ± 9.269	9.515 ± 5.124	9.953 ± 6.774
Menopausal state	Premenopause	19.664 ± 5.602	75	18.907 ± 5.804	9.340 ± 5.798	8.285 ± 5.229	15.155 ± 6.118	14.556 ± 5.402	8.580 ± 3.756	8.736 ± 3.632
Menopausal state	Post menopause	73.529 ± 50.564	44	17.325 ± 5.308	7.471 ± 6.652	7.658 ± 5.294	17.583 ± 9.432	16.954 ± 10.784	10.663 ± 5.739	10.850 ± 7.954
Clinical stage	≤ Stage 2	18.859 ± 5.564	64	18.391 ± 5.528	8.732 ± 6.368	7.911 ± 5.665	14.430 ± 5.900	15.320 ± 5.357	8.261 ± 3.864	9.245 ± 3.695
Clinical stage	> Stage 3	19.471 ± 6.759	55	18.471 ± 5.927	8.823 ± 5.809	8.326 ± 4.679	17.731 ± 8.500*	15.240 ± 9.567	10.409 ± 5.028*	9.546 ± 6.973
Histological grade	Level 1	17.963 ± 4.995	27	16.700 ± 4.955	4.788 ± 3.183	6.125 ± 3.646	13.913 ± 4.946	11.031 ± 4.188	8.638 ± 4.428	6.619 ± 2.710
	Level 2	18.000 ± 5.664	45	17.689 ± 5.234	9.591 ± 7.328	8.706 ± 6.497	15.291 ± 6.758	16.157 ± 5.402	8.314 ± 3.742	9.700 ± 3.813
	Level 3	21.230 ± 6.902	47	20.407 ± 6.314	10.107 ± 4.751**	8.496 ± 3.986	17.811 ± 8.924	16.874 ± 10.149*	10.740 ± 5.279	10.659 ± 7.506**
Intraductal carcinoma	No	19.390 ± 6.121	70	18.798 ± 5.693	9.070 ± 6.180	8.518 ± 5.435	14.590 ± 7.160	15.330 ± 6.205	8.945 ± 4.179	8.775 ± 4.916
Intraductal carcinoma	Have	18.864 ± 6.123	49	18.046 ± 5.698	8.467 ± 6.058	7.662 ± 5.029	15.997 ± 7.793	16.469 ± 8.333	9.487 ± 4.879	9.997 ± 5.781
Lymph nodes	Non-metastasis	17.159 ± 5.495	47	16.906 ± 5.452	10.865 ± 8.113	9.306 ± 7.426	12.724 ± 5.414	15.729 ± 4.995	7.176 ± 3.647	10.159 ± 3.744
Lymph nodes	Metastasis	19.671 ± 6.173	72	18.844 ± 5.702	8.198 ± 5.346	7.763 ± 4.460	16.761 ± 7.553	15.163 ± 8.040	9.771 ± 4.597*	9.165 ± 5.733
Hormone receptor status	ER positive group	18.725 ± 5.861	78	18.279 ± 5.425	8.867 ± 6.267	8.219 ± 5.222	15.585 ± 6.822	15.110 ± 6.156	9.265 ± 4.445	8.865 ± 4.332
Hormone receptor status	ER negative group	20.059 ± 6.344	41	18.900 ± 5.860	8.962 ± 5.954	8.228 ± 5.335	16.086 ± 7.986	14.941 ± 9.110	9.217 ± 4.794	9.734 ± 6.524

Emax = maximum elasticity; Emean = mean elasticity; Esd = stand deviation; Eratio = elasticity ratio. Compared with corresponding subgroup, *P < 0.05; **P < 0.01

Back to article page

ISSN: 1471-2342

Contact us

General enquiries: journalsubmissions@springernature.com

BMC Medical Imaging

Contact us